Back to Treatments

Treatment

Nintedanib

1
Conditions
1
Trials
3,500
Participants
40%
Average Safety

Condition Evidence

Interstitial lung disease and pulmonary sarcoidosis

1 trials · 3,500 participants

65% effectiveness · 40% safety
Nintedanib | DFDA